Experimental Psilocybin Dose Linked to Temporary Cognitive and Physical Improvements in Elderly Alzheimer’s Patient
A recent case study from Brazil has drawn attention after reporting that a high dose of psilocybin-containing mushrooms was associated with notable, though temporary, improvements in an elderly patient with advanced Alzheimer’s disease.
ScienceAlert
The report, published in Frontiers in Neuroscience and summarized by ScienceAlert, describes an woman in her 80s who had experienced severe cognitive decline for years. Before treatment, she was largely unable to communicate beyond single words, required assistance with daily activities, and suffered long-term urinary incontinence.
ScienceAlert
High-dose psilocybin administration
Researchers administered an initial oral dose of approximately 5 grams of psilocybin-containing mushrooms under clinical supervision, followed by a second 3-gram dose one month later. The first session induced a prolonged altered state, followed by delayed but striking changes in behavior and function.
ScienceAlert
Roughly 19 hours after the initial dose, the patient began speaking to herself and showing increased verbal activity. In the following days, caregivers and researchers observed improvements including regained bladder control, increased mobility, and improved social engagement such as eye contact and conversational responsiveness.
ScienceAlert
During the second supervised session, the patient remained verbally expressive and displayed emotional responses, including recounting vivid imagery and expressing positive feelings about the experience.
Observed improvements and limitations
Researchers noted changes in emotional expression, humor, and movement, as well as sustained improvements in continence following years of impairment. However, they emphasized that these effects did not indicate a reversal of Alzheimer’s disease itself.
ScienceAlert
The authors also highlighted important limitations: the study was observational, involved a single patient, and lacked standardized cognitive testing and brain activity monitoring during the psychedelic experience. As a result, the findings cannot establish causation or generalize to other patients.
What the findings may suggest
The researchers propose that psilocybin may temporarily alter brain network activity in ways that allow access to residual cognitive or functional capacity that remains even in advanced neurodegeneration. However, they stress that this is speculative and requires controlled clinical trials for verification.
ScienceAlert
Experts in the field note that psychedelics like psilocybin are already being investigated for their effects on depression, anxiety, and quality of life in patients with cognitive decline, but their role in treating Alzheimer’s disease remains unproven.
Early-stage research continues
Ongoing studies are exploring whether psilocybin, when administered in controlled clinical environments, can improve mood and quality of life in people with mild cognitive impairment or early Alzheimer’s disease. However, researchers caution that many promising dementia treatments have failed in later clinical trials.
For now, scientists describe the findings as an intriguing hypothesis-generating case rather than evidence of a new therapy.
Source: SciencAlert
0 comments